Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 6/20 | 0.65 |
| ▸ | RBPJ | Q06330 | 4/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.62 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.62 |
| ▸ | NOTCH3 | Q9UM47 | 2/20 | 0.58 |
| ▸ | CCKBR | P32239 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289207 | 1.00 | NOTCH1 (0.65) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287669 | 0.93 | NOTCH1 (0.68) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL6005977 | 0.87 | NOTCH1 (0.72) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL5016371 | 0.86 | PSEN1 (0.73) | NOTCH1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3287317 | 0.85 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL5839093 | 0.85 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL8244069 | 0.85 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3293655 | 0.85 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287198 | 0.85 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287486 | 0.85 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | NOTCH1 528/4885RBPJ 3834/4885PSEN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.